Head And Neck Squamous Cell Carcinoma Hnscc clinical trials

Explore recruiting head and neck squamous cell carcinoma hnscc clinical trials.

Recruiting head and neck squamous cell carcinoma hnscc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Head And Neck Squamous Cell Carcinoma Hnscc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Spain, Netherlands, Belgium, Poland, France, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)

Belgium, Poland, France, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRIME H&N study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

DAHANCA 30 Et randomiseret non-inferiority studie af hypoxi-profilvejledt nimorazolbehandling i forbindelse med primær strålebehand-ling af planocellulære hoved-halskarcinomer

Norway, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)

France, Spain, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Head And Neck Squamous Cell Carcinoma Hnscc trials by city

Head And Neck Squamous Cell Carcinoma Hnscc in Toronto Head And Neck Squamous Cell Carcinoma Hnscc in Vancouver Head And Neck Squamous Cell Carcinoma Hnscc in Montreal Head And Neck Squamous Cell Carcinoma Hnscc in Calgary Head And Neck Squamous Cell Carcinoma Hnscc in Edmonton Head And Neck Squamous Cell Carcinoma Hnscc in Ottawa Head And Neck Squamous Cell Carcinoma Hnscc in Winnipeg Head And Neck Squamous Cell Carcinoma Hnscc in Quebec City Head And Neck Squamous Cell Carcinoma Hnscc in Hamilton Head And Neck Squamous Cell Carcinoma Hnscc in Kitchener Head And Neck Squamous Cell Carcinoma Hnscc in London Head And Neck Squamous Cell Carcinoma Hnscc in Halifax Head And Neck Squamous Cell Carcinoma Hnscc in New York Head And Neck Squamous Cell Carcinoma Hnscc in Los Angeles Head And Neck Squamous Cell Carcinoma Hnscc in Chicago Head And Neck Squamous Cell Carcinoma Hnscc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease